Lurbinectedin is not currently approved for all cancer types. As per the sources provided, the drug has received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of metastatic small cell lung cancer (SCLC) [3]. However, the drug is still under investigation for its efficacy in other cancer types, including ovarian, endometrial, and breast cancers [2]. The drug has shown promising results in clinical trials for these cancers, and further studies are being conducted to evaluate its effectiveness [2]. The drug patent watch website confirms that the drug is still in the clinical trial phase for other cancer types [1]. Therefore, it can be concluded that lurbinectedin is currently approved for the treatment of metastatic SCLC only, and its effectiveness in other cancer types is still being evaluated.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532454/
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer